- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07365319
Eine Sicherheits- und Wirksamkeitsstudie von EIK1001 in Kombination mit Pembrolizumab und Chemotherapie bei Teilnehmern mit nicht-kleinzelligem Lungenkrebs im Stadium 4. (TeLuRide-008)
Eine globale, multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-2/3-Studie von EIK1001 in Kombination mit Pembrolizumab und Chemotherapie bei Teilnehmern mit nicht-kleinzelligem Lungenkrebs im Stadium 4 (TeLuRide-008).
This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
This is a global, multicenter, double-blind, placebo-controlled, randomized adaptive Phase 2/3 study to evaluate the clinical activity and safety of EIK1001 administered IV in combination with pembrolizumab and histologically appropriate chemotherapy (pemetrexed plus either carboplatin or cisplatin) to participants with Stage 4 non-squamous or (carboplatin plus either paclitaxel or nab-paclitaxel) for participants with squamous NSCLC who have not received prior systemic therapy. The study is conducted in 2 phases (Phase 2 and Phase 3) and analyzed in 3 parts (dose optimization, dose expansion and confirmatory hypothesis testing).
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Elelta Shiferraw
- Telefonnummer: 314-209-3659
- E-Mail: shiferrawe@eikontx.com
Studienorte
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentinien, 2000
- Rekrutierung
- Fundación de Estudios Clínicos
-
-
-
-
New South Wales
-
Frenchs Forest, New South Wales, Australien, 2086
- Rekrutierung
- Cancer Care Northern Beaches
-
Waratah, New South Wales, Australien, 2298
- Rekrutierung
- Calvary Mater Newcastle Hospital
-
-
Victoria
-
Frankston, Victoria, Australien, 3199
- Rekrutierung
- Peninsula and Southeast Oncology (PASO) Medical
-
Saint Albans, Victoria, Australien, 3021
- Rekrutierung
- Sunshine Hospital - Western Health
-
-
-
-
-
Brussels, Belgien, 1020
- Rekrutierung
- Centre Hospitalier Universitaire Brugmann
-
-
-
-
-
Brasília, Brasilien, 71635-580
- Rekrutierung
- Hospital Brasília Unidade Lago Sul
-
-
Ceará
-
Fortaleza, Ceará, Brasilien, 60336-232
- Rekrutierung
- CRIO - Centro Regional Integrado de Oncologia
-
-
Espírito Santo
-
Cachoeiro de Itapemirim, Espírito Santo, Brasilien, 29308-065
- Rekrutierung
- Hospital Evangélico de Cachoeiro de Itapemirim
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasilien, 40170-110
- Rekrutierung
- Nucleo de Oncologia da Bahia
-
-
Rio Grande do Sul
-
Santa Maria, Rio Grande do Sul, Brasilien, 97015-450
- Rekrutierung
- Clinica de Hematologia e Oncologia Viver Ltda
-
-
Rio de Janeiro
-
Rio de Janeiro, Rio de Janeiro, Brasilien, 22250-905
- Rekrutierung
- Oncoclinicas Rio de Janeiro
-
-
-
-
-
Hamburg, Deutschland, 22087
- Rekrutierung
- Katholische Marienkrankenhaus gGmbH
-
-
Saxony
-
Dresden, Saxony, Deutschland, 01307
- Rekrutierung
- University Hospital Carl Gustav Carus Dresden
-
-
-
-
-
Athens, Griechenland, 11516
- Rekrutierung
- Henry Dunant Hospital Center
-
Thessaloniki, Griechenland, 55535
- Rekrutierung
- 4th Department of Medical Oncology, European Interbalkan Medical Center
-
-
Central Macedonia
-
Thessaloniki, Central Macedonia, Griechenland, 55535
- Rekrutierung
- Hospital Genesis
-
-
-
-
-
Roma, Italien, 00128
- Rekrutierung
- Policlinico Campus Bio-Medico
-
-
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 31-864
- Rekrutierung
- GCPMED Sp. z o.o., Centrum Medyczne iMed24
-
-
-
-
Cluj
-
Cluj-Napoca, Cluj, Rumänien, 400641
- Rekrutierung
- Medisprof Cancer Center
-
-
-
-
-
Barcelona, Spanien, 08028
- Rekrutierung
- Instituto Oncologico Dr. Rosell (IOR)
-
Girona, Spanien, 17007
- Rekrutierung
- Institut Catala D'Oncologia de Girona
-
Málaga, Spanien, 29004
- Rekrutierung
- Hospital Quirónsalud Málaga
-
-
Cadiz
-
Jerez de la Frontera, Cadiz, Spanien, 11407
- Rekrutierung
- Hospital Universitario de Jerez de la Frontera
-
-
Castellón
-
Castellon, Castellón, Spanien, 12006
- Rekrutierung
- Consorci Hospitalari Provincial de Castello
-
-
Malaga
-
Málaga, Malaga, Spanien, 29011
- Rekrutierung
- Hospital Regional Universitario de Malaga
-
-
-
-
Gauteng
-
Saxonwold, Gauteng, Südafrika, 2196
- Rekrutierung
- The Medical Oncology Centre of Rosebank
-
-
Western Cape
-
George, Western Cape, Südafrika, 6529
- Rekrutierung
- Task Eden
-
-
-
-
-
Seoul, Südkorea, 03181
- Rekrutierung
- Kangbuk Samsung Medical Center (KBSMC)
-
-
Daegu
-
Daegu, Daegu, Südkorea, 42415
- Rekrutierung
- Yeungnam University College of Medicine
-
-
Guro-gu
-
Seoul, Guro-gu, Südkorea, 08308
- Rekrutierung
- Korea University Medical Center-Korea University Guro Hospital - Women's Cancer Center
-
-
Incheon Gwang'Yeogsi
-
Incheon, Incheon Gwang'Yeogsi, Südkorea, 21565
- Rekrutierung
- Gachon University - Gil Medical Center
-
-
Jeollanam-do
-
Hwasun, Jeollanam-do, Südkorea, 58128
- Rekrutierung
- Chonnam National University Hwasun Hospital (CNUHH)
-
-
-
-
Alabama
-
Daphne, Alabama, Vereinigte Staaten, 36526
- Rekrutierung
- Southern Cancer Center, P.C.
-
-
California
-
Glendale, California, Vereinigte Staaten, 91204
- Rekrutierung
- Los Angeles Cancer Network
-
Orange, California, Vereinigte Staaten, 92868
- Rekrutierung
- Providence St. Joseph Hospital
-
-
Colorado
-
Pueblo, Colorado, Vereinigte Staaten, 81103
- Rekrutierung
- Rocky Mountain Cancer Centers, LLP
-
-
Florida
-
Doral, Florida, Vereinigte Staaten, 33172
- Rekrutierung
- Omnicure Clinical Research
-
Plantation, Florida, Vereinigte Staaten, 33322
- Rekrutierung
- Florida Clinical Trials Group
-
Tamarac, Florida, Vereinigte Staaten, 33321
- Rekrutierung
- Florida Clinical Trials Group - Tamarac
-
-
Illinois
-
Peoria, Illinois, Vereinigte Staaten, 61637
- Rekrutierung
- OSF Saint Francis Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87102
- Rekrutierung
- University of New Mexico - Comprehensive Cancer Center
-
-
New York
-
Mineola, New York, Vereinigte Staaten, 11501
- Rekrutierung
- NYU Langone Hospital Long Island
-
New York, New York, Vereinigte Staaten, 10016
- Rekrutierung
- NYU Langone Hospital Manhattan
-
The Bronx, New York, Vereinigte Staaten, 10461
- Rekrutierung
- Jacobi Medical Center - Albert Einstein College of Medicine
-
White Plains, New York, Vereinigte Staaten, 10601
- Rekrutierung
- White Plains Hospital
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Rekrutierung
- Tennessee Oncology
-
-
Texas
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Rekrutierung
- The Center for Cancer and Blood Disorders
-
-
Virginia
-
Blacksburg, Virginia, Vereinigte Staaten, 24060
- Rekrutierung
- Blue Ridge Cancer Center
-
Fairfax, Virginia, Vereinigte Staaten, 22031
- Rekrutierung
- Virginia Cancer Specialists, PC
-
Winchester, Virginia, Vereinigte Staaten, 22601
- Rekrutierung
- Shenandoah Oncology P.C.
-
-
-
-
-
Linz, Österreich, 4020
- Rekrutierung
- Kepler Universitaetsklinikum
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
-
Participant must be ≥ 18 years old at the time of signing the informed consent.
-
Participant has a life expectancy of at least 3 months.
-
Participant has histologically or cytologically confirmed Stage 4 NSCLC predominately squamous or non-squamous) and is considered a candidate for standard therapy with pembrolizumab and chemotherapy. Participants with NSCLC-NOS (not otherwise specified) will be considered as non-squamous NSCLC.
-
Participant must have documented evidence that mutation-directed therapy is not indicated, based on the absence of tumor-activating mutations or fusions (e.g., but not limited to EGFR, ALK, RET, ROS1, BRAF) for which approved first-line targeted therapies are available to the participant in their respective country.
-
Participant has at least 1 lesion with measurable disease at Baseline according to RECIST 1.1 as determined locally. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions.
-
Participant has not received prior systemic therapy for advanced/metastatic NSCLC.
Note: Participants who received adjuvant or neoadjuvant treatment (after surgery and/or radiation therapy) and developed recurrent or metastatic disease more than 1 year after completing therapy are eligible.
-
Participant has an ECOG Performance Status of 0 to 1 assessed no more than 10 days before start of the treatment.
-
Participant has tumor tissue available for PD-L1 testing from a site that was not radiated prior to biopsy, and was obtained, ideally, after diagnosis of metastatic disease. Biopsies obtained prior to receipt of adjuvant/neoadjuvant chemotherapy will be permitted if recent biopsy is not feasible (provided the specimen is < 3yrs old).
Key Exclusion Criteria:
- has small cell elements present histologically and/or the tumors are not predominantly non-squamous or squamous NSCLC.
- is currently actively enrolled in or has recently participated in a study of an investigational agent and received investigational therapy within 4 weeks or 5 half-lives (whichever is longer) of administration of EIK1001 or placebo.
- has had major surgery (< 3 weeks prior to the first dose of study intervention administration).
- has received a live-virus vaccination within 30 days of the start of study intervention initiation.
- has received radiation therapy within 7 days of the first dose of study intervention administration.
- has completed palliative radiotherapy within 7 days of the first dose of study intervention administration.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Placebo-Komparator: Arm 1 (Placebo in Combination with SOC)
Participants in this arm will receive EIK1001 Placebo + Standard of Care (SOC). |
Placebo control PD-1 inhibitor SOC Chemotherapy for squamous NSCLC SOC Chemotherapy for squamous NSCLC SOC Chemotherapy for non-squamous NSCLC |
|
Experimental: Arm 2 (EIK1001 in Combination with SOC)
Participants in this arm will receive EIK1001 (Selected Dose 1) + Standard of Care (SOC). |
PD-1 inhibitor SOC Chemotherapy for squamous NSCLC SOC Chemotherapy for squamous NSCLC SOC Chemotherapy for non-squamous NSCLC EIK1001 is a Toll like receptor 7/8 (TLR 7/8) dual agonist |
|
Experimental: Arm 3 (EIK1001 in Combination with SOC)
Participants in this arm will receive EIK1001 (Selected Dose 2) + Standard of Care (SOC). |
PD-1 inhibitor SOC Chemotherapy for squamous NSCLC SOC Chemotherapy for squamous NSCLC SOC Chemotherapy for non-squamous NSCLC EIK1001 is a Toll like receptor 7/8 (TLR 7/8) dual agonist |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression-free survival (PFS)
Zeitfenster: Through study completion, up to 6 years
|
Progression-free survival (PFS) is defined as the time from the first dose of the study medication to the first documented disease progression according to RECIST 1.1 by BICR, or death due to any cause, whichever occurs first |
Through study completion, up to 6 years
|
|
Overall survival (OS)
Zeitfenster: Through study completion, up to 10 years
|
OS defined as the time from the first dose of study medication to death due to any cause |
Through study completion, up to 10 years
|
|
Objective Response (OR)
Zeitfenster: Through study completion, up to 6 years
|
Objective response (OR) is defined as participants who demonstrate complete response (CR) or partial response (PR) by RECIST 1.1 as assessed by the Investigator, adverse events (AEs), and discontinuation of study intervention due to an AE (Dose Optimization Only). |
Through study completion, up to 6 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Objective response (OR)
Zeitfenster: Up to 6 years
|
Objective response (OR) is defined as participants who have a confirmed complete response (CR) or partial response (PR) according to RECIST 1.1 by BICR |
Up to 6 years
|
|
Duration of response (DOR)
Zeitfenster: Up to 6 years
|
DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR, according to RECIST 1.1 by BICR. |
Up to 6 years
|
|
Progression-free survival (PFS) by Investigator
Zeitfenster: Up to 6 years
|
Progression-free survival (PFS) is defined as the time from the first dose of the study medication to the first documented disease progression according to RECIST 1.1 by Investigator, or death due to any cause, whichever occurs first. |
Up to 6 years
|
|
Overall Response Rate (ORR) by Investigator
Zeitfenster: Up to 6 years
|
Objective Response as defined by participants who demonstrate confirmed CR or PR according to RECIST 1.1 by Investigator. |
Up to 6 years
|
|
Duration of Response (DOR) by Investigator
Zeitfenster: Up to 6 years
|
DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR, according to RECIST 1.1 by Investigator. |
Up to 6 years
|
|
Incidence of Adverse Events (AEs)
Zeitfenster: Up to 2.5 years
|
Adverse Events (AEs) and discontinuation of study treatment due to any AE. |
Up to 2.5 years
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Studienleiter: Nishitha Reddy, Eikon Therapeutics
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach Standort
- Neubildungen
- Erkrankungen der Atemwege
- Lungenkrankheit
- Neubildungen der Atemwege
- Thoraxneoplasmen
- Lungentumoren
- Karzinom, bronchogen
- Bronchiale Neubildungen
- Karzinom, nicht-kleinzellige Lunge
- Aminosäuren, Peptide und Proteine
- Organische Chemikalien
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Anorganische Chemikalien
- Chlorverbindungen
- Stickstoffverbindungen
- Koordinationskomplexe
- Guanine
- Hypoxanthen
- Purinonen
- Purines
- Glutamaten
- Aminosäuren, saur
- Aminosäuren
- Aminosäuren, Dicarboxylic
- Platinverbindungen
- Pemetrexed
- Carboplatin
- Cisplatin
- Pembrolizumab
- 130-nm-Albumin-gebundenes Paclitaxel
- CP -Protokoll
Andere Studien-ID-Nummern
- EIK1001-008
- 2025-525013-23-00 (Ctis)
- KEYNOTE-G57 (Andere Kennung: Merck Sharp & Dohme LLC)
- MK-3475-G57 (Andere Kennung: Merck Sharp & Dohme LLC)
- 2025 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .